HS-10502

N/A

Report date: 2024/11/25 11:57:34
NME

Base Information

Drug NameHS-10502
Drug Alias NameHS-10502
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitors
TargetsPoly (ADP-Ribose) polymerase 1
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsOvarian Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A